ARWR
$57.40+0.03 (+0.05%)
Arrowhead Pharmaceuticals, Inc.
Recent News
SRPT Stock Up as Enrollment Begins in DMD Gene Therapy Safety Study
Sarepta gains as enrollment begins in a new ENDEAVOR study cohort testing a sirolimus regimen to improve Elevidys safety in DMD patients.
Arrowhead (ARWR) FQ1 2026 Revenue Hits $264M as REDEMPLO Approval Marks Commercial Shift
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) is one of the best multibagger stocks to invest in according to billionaires. On February 5, Arrowhead Pharmaceuticals achieved a strategic turning point in FQ1 2026, transitioning into a commercial-stage organization following the US FDA approval of its first medicine, REDEMPLO (plozasiran). This siRNA therapeutic, designed to treat familial chylomicronemia syndrome/FCS, […]
Arrowhead Pharmaceuticals Teases Q3 Data Wave: SHASTA-3/4, RNAi Dimer and ARO-MAPT Readouts Ahead
Arrowhead Pharmaceuticals (NASDAQ:ARWR) outlined a slate of expected clinical data updates during a discussion at the Leerink Partners Global Healthcare Conference in Miami, with management pointing to multiple readouts concentrated in the third quarter and additional updates expected in the second
Arrowhead Pharmaceuticals Teases 2026 Catalysts, Waylivra Launch Momentum at TD Cowen Conference
Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined a busy slate of clinical catalysts and a growing commercial footprint during a presentation at TD Cowen’s 46th Annual Healthcare Conference, emphasizing a pipeline that management said includes roughly 21 or 22 drug candidates in clinical s
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Cooling Share Price And Strong Long-Term Returns
With no single headline event setting the tone, Arrowhead Pharmaceuticals (ARWR) is drawing attention as investors weigh its recent share performance against current financial metrics and the breadth of its RNAi-focused pipeline. See our latest analysis for Arrowhead Pharmaceuticals. Arrowhead’s recent share price has cooled, with a 1 month share price return of 8.74% and a year to date decline of 6.67%. This follows a very large 1 year total shareholder return of around 2.3x and a 3 year...